Biophytis S.A

Biophytis SA operates as a clinical-stage biotechnology company. It specializes in the development of therapeutics that are aimed at slowing the degenerative processes associated with aging, including severe respiratory failure in patients suffering from COVID-19. Its products include Sarconeos (BIO101), which is used to treat sarcopenic obesity and Macuneos (BIO201), which is used to treat dry age-related macular degeneration (AMD). The company was founded by Stanislas Veillet and René Lafont on September 15, 2006 and is headquartered in Paris, France.

Biophytis SA operates as a clinical-stage biotechnology company. It specializes in the development of therapeutics that are aimed at slowing the degenerative processes associated with aging, including severe respiratory failure in patients suffering from COVID-19. Its products include Sarconeos (BIO101), which is used to treat sarcopenic obesity and Macuneos (BIO201), which is used to treat dry age-related macular degeneration (AMD). The company was founded by Stanislas Veillet and René Lafont on September 27, 2006 and is headquartered in Paris, France.

€11.1M of available cash and equivalents on December 31, 2022, and financing instruments for a total of €22M allowing financial visibility beyond mid 2024 Positive results of the Phase 2-3 COVA study for the treatment of severe COVID-19 with Sarconeos (BIO101) Early Access Program (EAP) submission in France by June 2023 while preparing filing for conditional marketing authorization in the USA and Europe for Sarconeos (BIO101) in COVID-19 PARIS, FRANCE and CAMBRIDGE, MA / ACCESSWIRE / April 18, 2023 / Biophytis SA (NasdaqCM:BPTS)(Euronext Growth Paris:ALBPS), ("Biophytis" or the "Company"), a clinical-stage biotechnology company focused on the development of therapeutics that slow the degenerative processes associated with aging, including severe respiratory failure in patients suffering from COVID-19, today announces its financial results for the year ended December 31, 2022, and provides updates on key perspectives for 2023. Stanislas Veillet, President and CEO of Biophytis, stated: "In a difficult economic and financial environment, 2022 was a crucial year for Biophytis.

Biophytis Announces 2022 Financial Results and 2023 Perspectives

Adoption of all resolutions Reduction of the nominal value of the share to 0.01 euro PARIS, FRANCE and CAMBRIDGE, MA / ACCESSWIRE / April 18, 2022 / Biophytis SA (Nasdaq CM :BPTS)(Euronext Growth Paris:ALBPS), ("Biophytis" or the "company"), a clinical-stage biotechnology company focused on the development of therapeutics that are aimed at slowing the degenerative processes associated with aging and improving functional outcomes for patients suffering from age-related diseases, today announces the approval by a very large majority of all resolutions presented by the company and falling within the remit of the Combined General Meeting. Thanks to the mobilization of shareholders, the CGM could be held on second call with a quorum of more than 20% of the shareholders present or represented.

Biophytis: Results of the Combined General Meeting on April 17, 2023

PARIS, FRANCE and CAMBRIDGE, MA / ACCESSWIRE / March 30, 2023 / Biophytis SA (NASDAQ:BPTS)(Euronext Growth Paris:ALBPS) (the "Company" or "Biophytis"), a clinical-stage biotechnology company focused on the development of therapeutics that slow the degenerative processes associated with aging, including severe respiratory failure in patients suffering from COVID-19, today informed that the Extraordinary General Meeting of the company held on March 30, 2023 could not be held on first notice, as the required quorum was not reached. The quorum necessary for holding an extraordinary General Meeting on first call IS 25%.

Biophytis: The Combined General Meeting Will Be Held on Second Call on April 17, 2023

Biophytis (NASDAQ: BPTS ) stock is seeing wild movement on Thursday morning but it's nothing for traders to be worried about. Instead, the company has undergone a ratio change for its American Depositary Shares (ADSs).

Why Is Biophytis (BPTS) Stock On The Move Today?

Biophytis presented Sarconeos (BIO101) as a possible treatment candidate for long COVID after hospitalization during the 13th annual International Conference on Frailty and Sarcopenia Research (ICFSR) PARIS, FRANCE / CAMBRIDGE, MA / ACCESSWIRE / March 27, 2023 / Biophytis SA (NasdaqCM:BPTS)(Euronext Growth Paris:ALBPS) (the "Company" or "Biophytis"), a clinical-stage biotechnology company focused on the development of therapeutics that slow the degenerative processes associated with aging, including severe respiratory failure in patients suffering from COVID-19, today announced that it has held a presentation on their drug candidate, Sarconeos (BIO101), as a possibility to cure long COVID after hospitalization, at the 13th annual International Conference on Frailty and Sarcopenia Research (ICFSR). The event was held in Toulouse, France from March 22 to March 24, 2023.

Biophytis: Biophytis Presented Sarconeos (BIO101) As A Possible Treatment Candidate for Long COVID After Hospitalization During The 13th Annual International Conference on Frailty and Sarcopenia Resea

Biophytis (NASDAQ: BPTS ) stock is taking off on Thursday after the company revealed results from a recent clinical trial. The big news affecting BPTS stock today comes from a Phase 2/3 study of Sarconeos as a treatment for severe respiratory failure in patients suffering from Covid-19.

Why Is Biophytis (BPTS) Stock Up 28% Today?

PARIS, FRANCE and CAMBRIDGE, MA / ACCESSWIRE / March 9, 2023 / Biophytis SA (NASDAQ:BPTS)(Euronext Growth Paris:ALBPS) (the "Company" or "Biophytis"), a clinical-stage biotechnology company focused on the development of therapeutics that slow the degenerative processes associated with aging, including severe respiratory failure in patients suffering from COVID-19, today announced that it presents the positive results of the phase 2-3 COVA study with Sarconeos (BIO101) in severe COVID-19 at the European Respiratory Society 2023 21st Lung Science Conference taking place in Estoril, Portugal, between the 9th and the 12th of March 2023. Professor Suzana Lobo, MD -Hospital de Base Da Faculdade de Medicina de São José Do Rio Preto, São Paulo, Brazil and Investigator of the COVA study in Brazil, will be holding an oralpresentation of the results titled "COVA clinical study:Results from a double-blind, placebo-controlled phase2/3 study to assess efficacy and safety of BIO101 in hospitalized severe COVID-19 patients.

Biophytis To Present Positive Results of Phase 2-3 COVA Study At ERS 2023 21st Lung Science Conference

Biorestorative Therapies

Diversified Healthcare Trust

Sonoma Pharmaceuticals

Troika Media Group

Penny stocks to watch with news. The post 5 Penny Stocks To Watch With Big News This Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

5 Penny Stocks To Watch With Big News This Week

Biophytis (NASDAQ: BPTS ) stock is rocketing higher on Thursday after the company signed a master service agreement with Intsel Chimos. With this agreement, Intsel Chimos will become the Pharmaceutical Operator/Exploitant in France for Sarconeos.

Why Is Biophytis (BPTS) Stock Up 42% Today?

Biophytis and Intsel Chimos signed a master service agreement under which Intsel Chimos will be the operating pharmaceutical company/exploitant, partner and distributor in France for the drug Sarconeos (BIO101) developed by Biophytis in the context of the early access program application. The application request for early access program, currently underway with the Haute Autorité de Santé (the French National Authority for Health, HAS), aims to allow treatment with Sarconeos (BIO101) for hospitalized patients with severe forms of COVID-19 as of the second half of 2023.

Biophytis Announces the Signature of a Master Service Agreement With Intsel Chimos, a Pharmaceutical Company That Will Operate Sarconeos (BIO101) in France for the Treatment of Severe Forms of COVID-19

Biophytis to present the early access application in France at a pre-filing meeting in March with the HAS Biophytis plans to file the application shortly after with the objective of obtaining early access authorization in France in the second quarter of 2023 Biophytis is pursuing in parallel the preparation of the conditional marketing authorization application due to the health emergency in Europe and the United States PARIS, FRANCE / CAMBRIDGE, MA / ACCESSWIRE / February 27, 2023 / Biophytis SA (NasdaqCM: BPTS, Euronext Growth Paris: ALBPS) (the "Company" or "Biophytis"), a biotechnology company focused on the development of drugs to slow the degenerative processes associated with aging, including severe respiratory failure in patients suffering from COVID-19, announced today that it has begun the process of early access application in France from the French National Authority for Health (HAS) for the treatment of severe COVID-19 with Sarconeos (BIO101). A pre-submission meeting with the HAS is scheduled for March and the application for early access authorisation should be submitted shortly after with the aim of obtaining authorisation in the second quarter of 2023.

Biophytis Initiates the Regulatory Process for an Early Access Authorization in France from the French National Authority for Health (HAS) for the Treatment with Sarconeos (BIO101) of Severe Forms of COVID-19

Delegation to the Board of Directors to reduce the nominal value Regrouping of the company's shares Renewal of Authorizations granted at the June 2022 AGM PARIS, FRANCE and CAMBRIDGE, MA / ACCESSWIRE / February 23, 2023 / Biophytis SA (NasdaqCM:BPTS, Euronext Growth Paris: ALBPS) (the "Company" or "Biophytis"), a biotech company focused on the development of drugs to slow the degenerative processes associated with aging, including severe respiratory failure in patients suffering from COVID-19, today announced it is convening an Extraordinary and Ordinary Shareholders' Meeting for March 30, 2023. Stanislas Veillet, CEO of Biophytis, stated: "Following COVA study positive results, we now wishe to regain the leeway and tools to refinance the company.

Biophytis To Host a Combined General Shareholder's Meeting on March 30, 2023

Biophytis (NASDAQ: BPTS ) stock is taking off on Thursday after the company released results from a Phase 2/3 clinical trial. That clinical trial covers the use of Sarconeos as a treatment for patients suffering from COVID-19-related respiratory failure.

Why Is Biophytis (BPTS) Stock Up 69% Today?

COVA study met primary end point with 44% significant reduction in the risk of respiratory failure or early death Filing for Early Access Programs to Sarconeos (BIO101) is being initated while preparing for Marketing Authorisation in Europe and the USA PARIS, FRANCE / CAMBRIDGE, MA / ACCESSWIRE / February 2, 2023 / Biophytis SA (NasdaqCM: BPTS, Euronext Growth Paris:ALBPS) (the "Company" or "Biophytis"), a clinical-stage biotechnology company focused on the development of therapeutics that slow the degenerative processes associated with aging, including severe respiratory failure in patients suffering from COVID-19, today released the final results from its phase 2-3 COVA clinical study evaluating Sarconeos (BIO101) in the treatment of COVID-19-related respiratory failure. Biophytis announces today final results following the reintegration of data from 54 patients, among 233 patients treated, that were missing in the Top Line analysis released on September 7, 2022.

Biophytis Announces Positive Final Results of the Phase 2-3 COVA Study with Sarconeos (BIO101) in Severe COVID-19

Cash and cash equivalents: €19.7m as of June 30, 2022 Net loss down 8% at €12.4m for first half of 2022 Publication of restated financial results as of December 31st, 2021 PARIS, FRANCE / CAMBRIDGE, MA / ACCESSWIRE / January 31, 2023 / Biophytis SA (NasdaqCM:BPTS, Euronext Growth Paris:ALBPS), ("Biophytis" or the "Company"), a clinical-stage biotechnology company focused on the development of therapeutics that slow the degenerative processes associated with aging, including severe respiratory failure in patients suffering from COVID-19, today publishes its interim financial report for the first half of 2022 and its adjusted financial results as of 31 December 2021. Financial results for the first half of 2022 Cash and cash equivalents.

Biophytis Publishes its Financial Results for the First Half of 2022

The Paris Court of appeal confirms the judgement of the Paris Conmmercial Court of 16th of March 2021 PARIS, FRANCE and CAMBRIDGE, MA / ACCESSWIRE / January 19, 2023 / Biophytis SA (NasdaqCM:BPTS)(Euronext Growth Paris:ALBPS) (the "Company" or "Biophytis"), a clinical-stage biotechnology company focused on the development of therapeutics that slow the degenerative processes associated with aging, including severe respiratory failure in patients suffering from COVID-19, today announces that on the 17th of January 2023 the Paris Court of Appeal rendered a decision in the case between Biophytis and Negma Group Ltd on the subject of the ORNANEBSA agreement concluded on21st August 2019. The Paris Court of Appeal has : - confirmed the judgment of the Paris Commercial Court of March 16, 2021 (hereinafter the "Judgment", see the press release of March 19, 2021, available on the Company's website); - ordered Biophytis to pay Negma 75,000 euros pursuant to Article 700 of the French Code of Civil Procedure as well as costs.

Biophytis: Judgment of the Paris Court of Appeal of 17 January 2023 in the Case Between Biophytis and Negma Group Ltd

PARIS, FRANCE and CAMBRIDGE, MA / ACCESSWIRE / January 12, 2023 / Biophytis SA (NasdaqCM:BPTS)(Euronext Growth Paris:ALBPS) (the "Company" or "Biophytis"), a clinical-stage biotechnology company focused on the development of therapeutics that slow the degenerative processes associated with aging, including severe respiratory failure in patientssuffering from COVID-19, received a deficiency notice from The Nasdaq Stock Market, Inc. ("Nasdaq") stating that the Company has not filed its financial information for the six-month period ended June 30, 2022 on a Form 6-K (the "Filing") and as a result the Company no longer complies with Nasdaq's listing rules for continued listing set forth in the Listing Rule 5250(c)(2). Nasdaq has informed the Company that it has 60 calendar days or until March 6, 2023 to submit a plan (the "Plan") as definitive as possible to regain compliance with the Nasdaq's continued listing requirements.

Biophytis To Take Appropriate Measures After Receiving Nasdaq Deficiency Notice

PARIS, FRANCE and CAMBRIDGE, MA / ACCESSWIRE / January 5, 2023 / Biophytis SA (NasdaqCM:BPTS, Euronext Growth Paris:ALBPS), ("Biophytis" or the "company") a clinical-stage biotechnology company focused on the development of therapeutics that slow the degenerative processes associated with aging, including severe respiratory failure in patients suffering from COVID-19, today announces its participation at the 41st JP Morgan Healthcare Conference, which will be held in San Francisco from the 9th to 12th of January 2023, and at the Invest Securities Biomed Event which will be held on the 24th of January 2023 in Paris. The JP Morgan Healthcare Conference is the world's largest healthcare investment event, connecting the world's leading healthcare companies, biotechs and technology innovators with members of the international financial community.

Biophytis Announces Its Participation in Two Major Investor Conferences in January, In the United States and In France: The JP Morgan Healthcare Conference and The Invest Securities Biomed

Following the positive post-hoc analysis of the phase 2-3 COVA clinical study strongly supporting therapeutic potential of Sarconeos (BIO101) in the treatment of pneumonia in COVID-19 patients at risk of repiratory failure, Biophytis management is inviting all of Biophytis' stakeholders to an online event with KOL. PARIS, FRANCE / CAMBRIDGE, MA / ACCESSWIRE / December 1, 2022 / Biophytis SA (NasdaqCM:BPTS)(Euronext Growth Paris:ALBPS) (the "Company" or "Biophytis"), a clinical-stage biotechnology company focused on the development of therapeutics that slow the degenerative processes associated with aging, including severe respiratory failure in patients suffering from COVID-19, today invited all its shareholders to an online event where Key Opinion Leaders as well as Biophytis' management will present an update of COVID-19 pandemic, the results of the phase 2-3 COVA study and discuss next regulatory steps for marketing authorization of Sarconeos (BIO101) in patients hospitalized with COVID-19 at risk of respiratory failure and death.

Biophytis Organises a Webcast with Key Opinion Leaders (KOL) On the Phase 2-3 Cova Study Results of Sarconeos (Bio101) In the Treatment of Pneumonia in Covid-19 Patients at Risk of Respiratory Failure

PARIS, FRANCE and CAMBRIDGE, MASSACHUSETTS / ACCESSWIRE / October 31, 2022 / Biophytis SA (NASDAQ:BPTS)(Euronext Growth Paris:ALBPS) (the "Company" or "Biophytis"), a clinical-stage biotechnology company focused on the development of therapeutics that slow the degenerative processes associated with aging, including severe respiratory failure in patients suffering from COVID-19, today publishes its key financial figures as of 30 June 2022 and announces that the audited consolidated financial statements previously published by the Company for the year ended December 31st, 2021 are being restated to correct the accounting treatment of the Kréos financing agreement signed in November 2021. Key financial data (unaudited) Cash position at €19.7million as of June 30, 2022 compared to €23.9 millions as of December 31, 2021 Operating loss of €11.9 million in H1 2022 compared to €10.5 million in H1 2021, due to higher share-based payment costs as a result of their accounting treatment under IFRS2, partially offset by lower clinical trials related costs Cash used by operating activities down 23% with €10.3 million used in H1 2022 compared to €13.4 million in H1 2021, due to lower clinical trial costs between these two periods.

Biophytis Publishes Its Key Financial Figures As at 30 June 2022, Announces a Restatement of the Financial Statements Published As of December 31st, 2021 and Provides an Update on the Operational Milestones

PARIS, FRANCE and CAMBRIDGE, MA / ACCESSWIRE / September 15, 2022 / Biophytis SA (NasdaqCM:BPTS)(Euronext Growth Paris:ALBPS) (the "Company" or "Biophytis"), a clinical-stage biotechnology company focused on the development of therapeutics that slow the degenerative processes associated with aging, including severe respiratory failure in patients suffering from COVID-19, made a presentation to investors on the 12th of September in New York, on the occasion of the 24th Global Investment Conference organised by the HC Wainwright bank, which is being held from 12 to 14 September 2022 in New York. During this oral presentation, Stanislas Veillet, CEO of Biophytis, gave an update on the company's clinical results, presented the first results of the phase 2-3 COVA study in COVID-19-related respiratory failure and detailed the company's next key steps.

Biophytis Participates in H.C. Wainwright 24th Annual Global Investment Conference

On July 16th July 2021, the Paris Court had imposed on Biophytis a penalty payment of EUR 1,500,000 in favour of Negma Group Ltd, following a judgment of the Paris Commercial Court On September 8th 2022, the Paris Court of Appeal partially reversed the judgment of the Enforcement Judge of the Paris Commercial Court Negma Group Ltd is ordered to reimburse Biophytis the sum of 1 million euros ARIS, FRANCE and CAMBRIDGE, MA / ACCESSWIRE / September 13, 2022 / Biophytis SA (NasdaqCM:BPTS)(Euronext Growth Paris:ALBPS) (the "Company" or "Biophytis"), a clinical-stage biotechnology company focused on the development of therapeutics that slow the degenerative processes associated with aging, including severe respiratory failure in patients suffering from COVID-19, today announces that on the 8th of September 2022 the Paris Court of Appeal rendered a decision in the case between Biophytis and Negma Group Ltd. As a reminder : In a judgment dated 16 July 2021, the enforcement judge of the Paris Court of First Instance had : Liquidated the penalty imposed by the judgment of the Paris Commercial Court of March 16, 2021 at EUR 1,500,000 and ; Ordered Biophytis to pay this amount to Negma; EUR 50,000 per day of delay (hereinafter the "Judgment") (see press release dated July 19, 2021, available on the Company's website).

The Paris Court of Appeal Rules in Favour of Biophytis in the Case Against Negma Group Ltd

PARIS, FRANCE and CAMBRIDGE, MA / ACCESSWIRE / September 7th, 2022 / Biophytis SA (NasdaqCM:BPTS)(Euronext Growth Paris:ALBPS) (the "Company" or "Biophytis"), a clinical-stage biotechnology company focused on the development of therapeutics that slow the degenerative processes associated with aging, including severe respiratory failure in patients suffering from COVID-19, today released top-line results from its phase 2-3 COVA clinical study evaluating Sarconeos (BIO101) in the treatment of COVID-19-related respiratory failure. The objective of the study was to investigate the efficacy and safety of Sarconeos (BIO101), 350 mg BID in hospitalized COVID-19 patients with hypoxemia, at risk of respiratory failure requiring high flow oxygen or mechanical ventilation, and death.

Biophytis Announces Very Promising Top Line Results of its Phase 2-3 COVA Clinical Study in COVID-19-Related Respiratory Failure

PARIS, FRANCE and CAMBRIDGE, MA / ACCESSWIRE / June 30, 2022 / Biophytis SA (NasdaqCM:BPTS, Euronext Growth Paris: ALBPS), a clinical-stage biotechnology company focused on the development of therapeutics that slow the degenerative processes associated with aging, including severe respiratory failure in patients suffering from COVID-19,today announces the issuance of the 160 Bonds Redeemable in Cash and New and Existing Shares (ORNANE) for a total amount of €4 million under its existing convertible bond agreement with Atlas, a specialized investment fund based in New York (United States) for €32 million (the "2021 Atlas Contract"). On June 14, 2021, Biophytis announced a convertible line of €32 million from Atlas.

Biophytis Announces the Drawing of the Second Tranche of Ornane Under the 2021 Atlas Contract for €4 Million

PARIS, FRANCE and CAMBRIDGE, MASSACHUSETTS / ACCESSWIRE / June 27, 2022 / Biophytis SA (NASDAQ:BPTS)(Euronext Growth Paris:ALBPS), ("Biophytis" or the "Company"), a clinical-stage biotechnology company focused on the development of therapeutics that slow the degenerative processes associated with aging and improve functional outcomes in patients suffering from age-related diseases, announced today that it is giving an oral presentation on the development of Sarconeos (BIO101) for the treatment of sarcopenia at the 15th International SCWD Congress (Society on Sarcopenia, Cachexia & Wasting disorders). This oral presentation given by Drs.

News for Biophytis S.A Stock (BPTS)